[Whitepaper] Real World Imaging™: Best Practices for Incorporating Clinical Imaging Data into Real World Evidence Programs
Current RWE programs have obvious gaps in available RWD, which rely heavily on historical sources such as EHRs and medical claims. Future enhancements need to include information from a greater variety of identified sources of RWE including diagnostic medical images.
Imaging data, traditionally difficult to locate, retrieve, view, de-identify and normalize at-scale is nevertheless one of the most important and critical clinical end points for many therapies. As an example, how do you measure the effectiveness of a cancer drug in reducing the size of a tumor if there is no imaging used for validation? Certainly not by looking at claims data set.
The high degree of non-interoperability in clinical imaging presented challenges, which were typically solved by trial sponsors at great cost and delay by utilizing manual efforts such as mailing physical media (CDs).
The many technical, process and structural barriers that have effectively segregated imaging data into unconnected data silos in the past are thankfully being broken down, and the time has finally come when imaging can be effectively utilized in the RWE process. Read the white paper on how to incorporate Real World Imaging™ into your RWE programs.